Appendix Table 1. Clinical parameters by site of first relapse

|  | Entire cohort(n=98) | Remission(n=6) | ILR(n=29) | DM(n=58) | No imaging(n=4) |
| --- | --- | --- | --- | --- | --- |
|  Demographics |
| Age, median [years] | 68 (34-80) | 65 (57-75) | 68 (51-78) | 68 (34-79) | 74 (68-80) |
| Sex, male | 50 (51.0%) | 2 (33.3%) | 14 (48.3%) | 33 (59.0%) | 0 (0%) |
|  Preoperative Risk Factors |
| CTCs≥1 | 7 (7.1%) | none | none | 7 (12.5%) | none |
| CA19-9 ≥ 200kU/l | 31/74 (41.9%)*24 missing*  | 2/4 (50%)*2 missing*  | 10/25 (40%)*2 missing*  | 18/42 (42.9%)*14 missing* | 1/2 (50%)*2 missing* |
| Tumour size on imaging> 25mm | 39/97 (40.2%)*1 missing* | 2 ( 33.3%) | 15 (51.7%) | 21/57 (36.8%)*1 missing* | 1 (25%) |
| Bilirubin > 50µmol/L | 75/94 (79.8%)*4 missing* | 5 (83.3%) | 20/27 (74.1%)*2 missing* | 47/56 (82.4%)*1 missing* | 2 (50%) |
|  Treatment |
| Neoadj. CTX: GEMZ FOLFIRINOX | 3 (3.0%)1 (1.0%) | nonenone | 2 (6.9%)none | 1 (1.7%)1 (1.7%) | nonenone |
| Operation: PPPD PD tot. Pancreatect. | 77 (78.6%)13 (13.2%)8 (8.2%) | 5 (83.3%)1 (16.7%)none | 23 (79.3%)4 (13.8%)2 (6.9%) | 46 (79.3%)7 (12.1%)5 (8.6%) | 2 (50%)1 (25%)1 (25%) |
| Venous resection | 36 (36.7%) | 3 (50%) | 16 (55.2%) | 15 (25.9%) | 1 (25%) |
| Adjuvant CTX FLV: GEMZ:  FLOX none:  | 53 (54.1%)6 (6.1%)3 (3.1%)36 (36.7%) | 5 (83.3%)nonenone1 (16.7%) | 14 (48.3%)3 (10.3%)1 (3.4%)11 (37.9%) | 31 (53.4%)3 (5.2%)1 (1.7%)22 (37.9%) | 2 (50%)nonenone2 (50%) |
|  Histopathologic results |
| Pancreatobiliary typeIntestinal type | 97 (99%)1 (1%) | 6 (100%) | 28 (96.6%)1 (3.4%) | 58 (100%) | 4 (100%) |
| UICC-stage (V7): Ib IIa IIb | 2 (2.0%)23 (23.5%)73 (74.5%) | none4 (66.7%)2 (33.3%) | none9 (31.0%)20 (69.0%) | 1 (1.7%)8 (13.8%)49 (84.5%) | 0 (0%)2 (50%)2 (50%) |
| pN1-status | 73 (74,5%) | 2 (33.3%) | 20 (69.0%) | 49 (84.5%) | 2 (50%) |
| R1-status | 61 (62.2%) | 3 (50%) | 20 (69.0%) | 35 (60.3%) | 3 (75%) |
| Vascular infiltration | 64 (65.3%) | 2 (33.3%) | 17 (55.1%) | 42 (72.4%) | 3 (75%) |
| Perineural infiltration | 91 (92.9%) | 4 (66.7%) | 28 (96.6%) | 54 (93.1%) | 4 (100%) |
| Comparison of patient, tumour, and treatment characteristics between different subgroups and the entire cohort. One single patient with death unrelated to cancer omitted from the subgroup presentation ILR: isolated locoregional recurrence, DM: distant metastasis, CTC: circulating tumour cell, GEMZ, FLV, FLOX, FOLFIRINOX: chemotherapy regimens; PD: pancreato-duodenectomy, PPPD: pylorus preserving PD |